Nicola Hobbs
Has grant
Senior Research Fellow
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
TREAT-HD: Delivering therapies to prevent neurodegeneration in Huntington’s disease’
Open Date: 2022-01-01
Close Date: 2027-01-01
Articles (10)
BACKGROUND Cognitive impairments are a hallmark of Huntington's disease (HD). METHODS Seventy‐one participants (43 HD gene‐expanded [HDGE], 28 healthy controls) from the HD‐Young Adult Study at two timepoints ≈ 4.7 years apart, completed the Cambridge Neuropsychological Test Automated Battery Rapid Visual Information Processing task and underwent resting‐state functional magnetic resonance imaging. We focused on predefined regions of interest that are involved in sustained attention. RESULTS HDGE individuals showed significantly poorer sustained attention than controls ( p adj = 0.007), with no significant change over time. Functional connectivity (FC) analyses revealed group differences in attention‐related networks, including the occipital–operculum and lentiform–orbitalis pathways. Time and group × time effects were also observed in frontal and parietal regions. DISCUSSION These findings demonstrate early and persistent attention deficits in HDGE, linked to altered FC in attention‐related circuits. This supports the presence of early cognitive dysfunction in HD and highlights potential compensatory and pathological changes in brain networks prior to the onset of clinical motor symptoms. Highlights We detail the discovery of early sustained attention deficits in Huntington's disease (HD) gene‐expanded (HDGE) young adults. These sustained attention deficits do not measurably decline over a 4.7‐year period. Altered functional connectivity was observed in attention‐related brain networks. Alterations in regions include occipital, opercular, lentiform, and frontal areas. Findings support attention as an early cognitive biomarker in HDGE young adults.
Year:
2026
Promising blood-based biomarkers of neuropathology have emerged with potential for therapeutic development and disease monitoring. However, these tools will require specialist tertiary services for integration into clinical management. Remote sampling for biomarker assessment could reduce burden of in-person clinical visits for such tests as well as increasing the sampling frequency and patient geographical outreach. Here, we evaluated a finger-prick blood collection approach for remote quantification of neurofilament light (NfL), a candidate blood-based biomarker evident in various neurological disorders, and other exploratory markers of neuronal injury and neuroinflammation (GFAP, tau). Matched samples from venepuncture and finger-prick were collected and processed into plasma and/or serum to directly compare analyte levels from a multi-disease discovery cohort ( n = 54 healthy controls; n = 57 Huntington’s disease (HD); n = 34 multiple sclerosis; n = 7 amyotrophic lateral sclerosis; n = 11 Parkinson’s disease), and a HD confirmatory cohort ( n = 57 healthy controls; n = 64 HD). Two delayed processing conditions were compared, three- and seven-day delay, simulating ambient shipment. Capillary NfL and GFAP concentrations were equivalent to those in venous serum and plasma in the multi-disease discovery cohort and HD confirmatory cohort. Only NfL remained stable after a seven-day processing delay in both venous and capillary serum samples. Using NfL concentrations from capillary blood, we replicated previously published disease group differences measured in venous blood. This data supports our finger-prick approach for remote collection and quantification of NfL. With the widespread applications for NfL across the spectrum of neurological disorders, this has the potential to transform disease monitoring, prognosis, and therapeutic development within clinical practice and research.
Year:
2025
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease with the age at which characteristic symptoms manifest strongly influenced by inherited HTT CAG length. Somatic CAG expansion occurs throughout life and understanding the impact of somatic expansion on neurodegeneration is key to developing therapeutic targets. In 57 HD gene expanded (HDGE) individuals, ~23 years before their predicted clinical motor diagnosis, no significant decline in clinical, cognitive or neuropsychiatric function was observed over 4.5 years compared with 46 controls (false discovery rate (FDR) > 0.3). However, cerebrospinal fluid (CSF) markers showed very early signs of neurodegeneration in HDGE with elevated neurofilament light (NfL) protein, an indicator of neuroaxonal damage (FDR = 3.2 × 10 −12 ), and reduced proenkephalin (PENK), a surrogate marker for the state of striatal medium spiny neurons (FDR = 2.6 × 10 −3 ), accompanied by brain atrophy, predominantly in the caudate (FDR = 5.5 × 10 −10 ) and putamen (FDR = 1.2 × 10 −9 ). Longitudinal increase in somatic CAG repeat expansion ratio (SER) in blood was a significant predictor of subsequent caudate (FDR = 0.072) and putamen (FDR = 0.148) atrophy. Atypical loss of interruption HTT repeat structures, known to predict earlier age at clinical motor diagnosis, was associated with substantially faster caudate and putamen atrophy. We provide evidence in living humans that the influence of CAG length on HD neuropathology is mediated by somatic CAG repeat expansion. These critical mechanistic insights into the earliest neurodegenerative changes will inform the design of preventative clinical trials aimed at modulating somatic expansion. ClinicalTrials.gov registration: NCT06391619 .
Year:
2025
Background Huntington's disease (HD) is a progressive neurodegenerative disorder. Models of brain biological age have shown evidence of accelerated aging relative to chronological age, but they typically rely on a single whole‐brain measure. While studies in other neurodegenerative diseases suggest region‐specific brain age models can provide deeper insights, this approach remains underexplored in HD. Such regional models could benefit clinical trials, which depend on sensitive biomarkers to monitor therapeutic effects. Objectives This study aimed to characterize region‐specific patterns of brain aging across Huntington's Disease Integrated Staging System (HD‐ISS) stages and evaluate their associations with cognitive, motor, and functional scores. Methods We employed machine learning to train brain age models on structural magnetic resonance imaging data from 1936 controls. These models were applied to 531 persons with HD. Associations between regional brain age gap, HD‐ISS stages, and clinical scores were assessed. Results Whole‐brain aging increased progressively at HD‐ISS stages 2 and 3. Region‐specific analyses revealed the dominance of subcortical, temporal, and parietal aging trajectories, which exhibited significant stage‐wise increases in brain age gap. A higher brain age gap in these regions was associated with declines in cognitive, motor, and functional performance. In contrast, insular and frontal regions showed flatter patterns and no significant associations with clinical measures. Conclusions This study highlights distinct region‐specific components of brain aging in HD. Regional analysis provides deeper insights into HD progression and could be employed as a sensitive biomarker for monitoring therapeutic effects in clinical trials. Future work should explore these findings in younger cohorts and investigate network‐specific aging with multimodal imaging. © 2025 International Parkinson and Movement Disorder Society.
Year:
2025
Background Huntington's disease (HD) is characterized by early, selective, progressive vulnerability of striatal medium spiny neurons (MSNs). Proenkephalin (PENK), a precursor of opioid peptides abundantly expressed in MSNs, is a promising biomarker of striatal integrity, but region‐specific associations and its potential for early‐stage discrimination have not been characterized. Objectives We investigated cross‐sectional and longitudinal associations between baseline cerebrospinal fluid (CSF) PENK concentration and regional brain atrophy, compared identified patterns with CSF neurofilament light (NfL), and evaluated PENK and NfL for discriminating between HD Integrated Staging System (HD‐ISS) stage 0 versus 1 in a far‐from‐onset HD gene‐expanded (HDGE) cohort. Methods Whole‐brain voxel‐based morphometry was performed in 149 participants (72 HDGE, 77 controls) cross‐sectionally and 88 participants (54 HDGE, 34 controls) longitudinally over a mean interval of 4.8 years. Voxel‐wise linear regression tested associations between baseline biofluid biomarkers and gray/white matter volume, adjusting for age, sex and CAG‐Age Product score, with false discovery rate correction. Logistic regression and receiver operating characteristic analyses assessed stage discrimination. Results Lower baseline CSF PENK predicted longitudinal gray and white matter loss, predominantly in the striatum bilaterally. Higher baseline CSF NfL predicted widespread longitudinal white matter loss. For stage discrimination, PENK (area under curve [AUC], 0.706; P = 0.0002) outperformed NfL (AUC, 0.661; P = 0.1596) with minimal gain from combining both (AUC, 0.714; joint P = 0.0007). Conclusions Lower baseline CSF PENK concentration predicted longitudinal striatal atrophy and CSF PENK outperformed CSF NfL in distinguishing HD‐ISS stages 0 and 1, supporting its role as a striatum‐specific biomarker with potential to enrich early‐stage HD trial cohorts. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Year:
2025
Huntington's Disease Integrated Staging System (HD-ISS) stages are likely inclusion criteria in future clinical trials. Stage 1 volumetric cut-offs were derived using the FreeSurfer longitudinal stream (LG). However, trials will require cross-sectional stream (CS) application with one MRI. Volumetric outputs are not robust to software type or version. T1-weighted images from 88 participants with MRIs from baseline and follow-up HD-YAS visits were segmented using both streams. CS calculated smaller caudate and putamen volumes adjusted for total intracranial volume, with greater reduction for larger volumes, shifting towards HD-ISS stage 1. CS-specific cut-offs need to be established before application to clinical trials.
Year:
2025
Background: Perivascular spaces (PVS) are fluid-filled cavities surrounding small cerebral blood vessels. There are limited reports of enlarged PVS across the grey matter in manifest Huntington’s disease (HD). Little is known about how PVS morphometry in the white matter may contribute to HD. Enlarged PVS have the potential to both contribute to HD pathology and affect the distribution and success of intraparenchymal and intrathecally administered huntingtin-lowering therapies. Objective: To investigate PVS morphometry in the global white matter across the spectrum of HD. Relationships between PVS morphometry and disease burden and severity measures were examined. Methods: White matter PVS were segmented on 3T T2 W MRI brain scans of 33 healthy controls, 30 premanifest HD (pre-HD), and 32 early manifest HD (early-HD) participants from the Vancouver site of the TRACK-HD study. PVS count and total PVS volume were measured. Results: PVS total count slightly increased in pre-HD (p = 0.004), and early-HD groups (p = 0.005), compared to healthy controls. PVS volume, as a percentage of white matter volume, increased subtly in pre-HD compared to healthy controls (p = 0.044), but not in early-HD. No associations between PVS measures and HD disease burden or severity were found. Conclusions: This study reveals relatively preserved PVS morphometry across the global white matter of pre-HD and early-HD. Subtle morphometric abnormalities are implied but require confirmation in a larger cohort. However, in conjunction with previous publications, further investigation of PVS in HD and its potential impact on future treatments, with a focus on subcortical grey matter, is warranted.
Year:
2024
Background: The Huntington’s Disease Integrated Staging System (HD-ISS) defined disease onset using volumetric cut-offs for caudate and putamen derived from FreeSurfer 6 (FS6). The impact of the latest software update (FS7) on volumes remains unknown. The Huntington’s Disease Young Adult Study (HD-YAS) is appropriately positioned to explore differences in FS bias when detecting early atrophy. Objective: Explore the relationships and differences between raw caudate and putamen volumes, calculated total intracranial volumes (cTICV), and adjusted caudate and putamen volumes, derived from FS6 and FS7, in HD-YAS. Methods: Images from 123 participants were segmented and quality controlled. Relationships and differences between volumes were explored using intraclass correlation (ICC) and Bland-Altman analysis. Results: Across the whole cohort, ICC for raw caudate and putamen was 0.99, cTICV 0.93, adjusted caudate 0.87, and adjusted putamen 0.86 (all p < 0.0005). Compared to FS6, FS7 calculated: i) larger raw caudate (+0.8%, p < 0.00005) and putamen (+1.9%, p < 0.00005), with greater difference for larger volumes; and ii) smaller cTICV (–5.1%, p < 0.00005), with greater difference for smaller volumes. The systematic and proportional difference in cTICV was greater than raw volumes. When raw volumes were adjusted for cTICV, these effects compounded (adjusted caudate +7.0%, p < 0.00005; adjusted putamen +8.2%, p < 0.00005), with greater difference for larger volumes. Conclusions: As new software is released, it is critical that biases are explored since differences have the potential to significantly alter the findings of HD trials. Until conversion factors are defined, the HD-ISS must be applied using FS6. This should be incorporated into the HD-ISS online calculator.
Year:
2024
Neuroimaging is increasingly being included in clinical trials of Huntington’s disease (HD) for a wide range of purposes from participant selection and safety monitoring, through to demonstration of disease modification. Selection of the appropriate modality and associated analysis tools requires careful consideration. On behalf of the EHDN Imaging Working Group, we present current opinion on the utility and future prospects for inclusion of neuroimaging in HD trials. Covering the key imaging modalities of structural-, functional- and diffusion- MRI, perfusion imaging, positron emission tomography, magnetic resonance spectroscopy, and magnetoencephalography, we address how neuroimaging can be used in HD trials to: 1) Aid patient selection, enrichment, stratification, and safety monitoring; 2) Demonstrate biodistribution, target engagement, and pharmacodynamics; 3) Provide evidence for disease modification; and 4) Understand brain re-organization following therapy. We also present the challenges of translating research methodology into clinical trial settings, including equipment requirements and cost, standardization of acquisition and analysis, patient burden and invasiveness, and interpretation of results. We conclude, that with appropriate consideration of modality, study design and analysis, imaging has huge potential to facilitate effective clinical trials in HD.
Year:
2024
Year:
2023
Collaborators (16)
Sarah J. Tabrizi
Joint Head, Department of Neurodegenerative Disease
-
Harpreet Hyare
Consultant Neuroradiologist and Hon Associate Professor
UCL Institute of Neurology, University College London
Mena Farag
University College London
Christelle Langley
University of Cambridge
Edward Wild
University College London
Lauren Byrne
University College London
Paul Zeun
UCL Institute of Neurology, University College London
Alexandra Durr
Professor, MD, PhD
Sorbonne Université
Rachael Scahill
University College London
Douglas Langbehn
Professor
Iowa State University
Nellie Georgiou-Karistianis
Deputy Dean, Academic and Graduate Affairs
MONASH UNIVERSITY
Blair Leavitt
Professor
The University of British Columbia
Jeffrey Long
University of Iowa Healthcare
Marc Ciosi
University of Glasgow
ANDREA MALASPINA
Head
-
Johan Gobom
Assoc. Prof
Region Östergötland
Make your next move.
Prepare your application
Review drafts before you send them.